Biotin in the US continued a measured uptrend into early February as balanced market conditions and steady end-user demand underpinned offers. Early January saw incremental upside that extended through the month, with late-January trading characterized by disciplined supplier behavior and consistent buying from nutraceutical and supplement formulators. Participants reported no meaningful supply disruptions, and sellers avoided aggressive discounting, enabling the market to consolidate gains. The tone remained constructive rather than volatile, with momentum driven by steady commercial demand rather than speculative activity. The nutraceuticals and dietary supplement sector remained the core support, with formulators continuing to procure biotin for finished products. The sector stayed robust, with no prominent weak end-use segments pulling prices lower. Upstream costs remained broadly unchanged, contributing to stable margins and modest price gains. Producers and distributors maintained firm offers, reflecting supply-side discipline and stable inventories. Looking ahead, the near-term outlook calls for stability with a gradual upside, supported by steady demand and balanced supply.
